A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: testing (1000), conducting tests (149)

NIHR_RTB_PIS-ICF_v5.0_04APR2024_Localised

Description
PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 5.0 04th April 2024 *If you require this information to
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v5.0-04APR2024-Localised.pdf

Capecitabine-Cisplatin-Trastuzumab

Description
Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CAPECITABINE-CISPLATIN-TRASTUZUMAB Regimen • Gastrointestinal (Upper) Cancer – Capecitabine-Cisplatin-Trastuzumab Indication • Trastuzumab, in combination with capecitabine
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Capecitabine-Cisplatin-Trastuzumab.pdf

Cisplatin-Fluorouracil-Trastuzumab

Description
Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CISPLATIN-FLUOROURACIL-TRASTUZUMAB Regimen • Gastrointestinal (Upper) Cancer – Cisplatin-Fluorouracil-Trastuzumab Indication • Trastuzumab, in combination with cisplatin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Cisplatin-Fluorouracil-Trastuzumab.pdf

NIHR_RTB_PIS-ICF_v5.0_04APR2024_Localised.cleaned

Description
PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 5.0 04th April 2024 *If you require this information to
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v5.0-04APR2024-Localised.cleaned.pdf

Lutetium-177 prostate specific membrane antigen (PSMA) therapy - patient information

Description
This factsheet explains what Lutetium-177 prostate specific membrane antigen (PSMA) therapy is, what the therapy involves, and what the possible
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Lutetium-177-prostate-specific-membrane-antigen-PSMA-therapy-2881-PIL.pdf

WHP Funding Call EOI_01.03.24

Description
Funding Call – Round 1 - PILOT Expression of Interest About Wessex Health Partners: 1. Wessex Health Partners (WHP) is the region’
Url
/Media/Southampton-Clinical-Research/Downloads/WHP-Funding-Call-EOI-01.03.24.docx

Talimogene laherparepvec (T-VEC)

Description
Chemotherapy Protocol SKIN CANCER Talimogene laherparepvec (T-VEC) Regimen • Skin – Talimogene laherparepvec (T-VEC) Indication • Talimogene laherparepvec (T-VEC) is recommended
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Talimogene-laherparepvec-T-VEC.pdf

NIHR BioBank participant info sheet_v4

Description
PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 2023 *If you require this information to
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-BioBank-participant-info-sheet-v4.pdf

Tisacel-Cytarabine (500)-Etoposide (150)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL – CYTARABINE (500) – ETOPOSIDE (150) Regimen This regimen will only
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cytarabine-500-Etoposide-150.pdf

Patient-initiated follow-up (PIFU) for CLL, SLL, LMZL and HCL - patient information

Description
This booklet contains a summary of patient-initiated follow-up (PIFU) for chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), leukaemic
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Patient-initiated-follow-up-PIFU-for-CLL-SLL-LMZL-and-HCL-3322-PIL.pdf
381 to 390 of 517
Previous … 37 38 39 40 41 … Next